Urological cancer comprises of the highest prevalence groups in the world and represents a growing burden on human healthcare[@b1][@b2]. Renal cell carcinoma (RCC) accounts for approximately 2--3% of all adult malignancies[@b1][@b3]. Prostate cancer is one of the most common cancers in men and the fifth most common cancer overall[@b4]. In bladder cancer, which ranks as the ninth most frequent malignancy, an estimated 386,300 new cases and 150,200 deaths from bladder cancer occurred in 2008 worldwide[@b1]. Despite the great progress in treatment of urological cancers, such as chemotherapy and molecular therapy, the clinical outcome remains not promising due to low objective response rate, tumor local recurrence or distal metastasis. In this condition, identification of patients who are prone to have a poor prognosis has become increasingly important for treatment selection and prognostic estimation. TNM classification and histological grade are clinically most-used prognostic indicators in malignancies. However, the accuracy of TNM classification remains poor in cancers and pathologic analysis for prognosis would miss any information associated patient-related factors[@b5]. This leaves a considerable space for the development of supplementary biomarkers to predict the prognosis of patients.

It is well documented that inflammation is a hallmark feature in the development and progression of cancer[@b6]. Increasing evidence suggests that inflammation can help incipient neoplasias to acquire hallmark capabilities and promote tumour growth and metastatic dissemination by sustaining a microenvironment[@b7][@b8]. C-reactive protein is a representative acute-phase protein and serves as a definitive marker for systemic inflammation[@b9]. In fact, a remarkable association between CRP and the p[oor]{.ul} survival in malignancies has been demonstrated, such as colorectal and lung cancers[@b6][@b8].

During the last decade, numerous studies explored the prognostic impact of CRP in urological cancers, including renal cell cancer, prostate cancer, bladder cancer and upper urinary urothelial carcinoma. Saito and Kihara concluded that CRP is a useful biomarker for urological cancers[@b10]. However, some studies failed to draw similar conclusions. Recently, several meta-analyses focused on the association between CRP and the survival of renal cell carcinoma or prostate cancer[@b11][@b12][@b13], but urothelial cancer and bladder cancer were not taken into account. More importantly, those reports included a relatively small number of studies. Many researchers have done a lot of studies on the prognostic role of CRP in urological cancers so that a growing number of related studies were published. Therefore, to confirm the prognostic significance of baseline serum CRP in urologic cancers, we gathered the available clinical research evidence and carried out a comprehensive meta-analysis. In this study, we applied a stricter inclusion/exclusion criteria, included much more recent studies, and discussed other important factors, especially the cutoff of CRP level.

Results
=======

Study selection
---------------

[Figure 1](#f1){ref-type="fig"} shows the process of study selection. We identified 650 possibly eligible articles through searching the Pubmed (n = 229) and EMBASE databases (n = 421) but 263 articles were excluded due to duplication. After carefully reviewing the titles and abstracts of 387 articles by the two authors (L.Z, X.C), 89 articles were retained for further examination. Based on the detailed information in full-texts, 45 articles were excluded as documented in [Figure 1](#f1){ref-type="fig"}. Finally, a total of 44 studies comprised 9174 cases were included for our quantitatively analysis.

Characteristics of included studies
-----------------------------------

Characteristics of included studies were summarized in [Table 1](#t1){ref-type="table"}. 44 observational studies were published from 1997 to 2014. All studies met all six points for quality evaluation. Most of these studies were conducted in Asia (n = 31), Europe (n = 11) and North America (n = 2). Of these studies, 6 explored the CRP in the prognosis of prostate cancer[@b14][@b15][@b16][@b17][@b18][@b19], 27 of renal cell carcinoma[@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46] and 11 of urothelial carcinoma originating from bladder (n = 6) and upper urinary tract (n = 5)[@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57]. The number of patients ranged from 30 to 1161 among the studies. As for the survival outcomes, 21 articles evaluated the association of CRP and OS. Prognostic role of CRP in CSS or disease specific survival (DSS) was evaluted in 25 articles.

Outcome
-------

In renal cell carcinoma, high CRP yielded a worse CSS (random-effect model; \[HR\] = 1.65, 95% \[CI\] = 1.29--2.10; p \< 0.01) ([Fig. 2A](#f2){ref-type="fig"}) and OS (random-effects model; \[HR\] = 1.97, 95% \[CI\] = 1.58--2.44; p \< 0.01) ([Fig. 2B](#f2){ref-type="fig"}). The multivariable HRs (95% CI) of prostate cancer for CSS and OS were 1.91 (fixed-effect model; \[HR\] = 1.47; 95% CI = 1.10--1.95; p \< 0.01) ([Fig. 3A](#f3){ref-type="fig"}) and 1.77 (fixed-effects model; \[HR\] = 1.76, 95%CI = 1.39--2.22; p \< 0.01) ([Fig. 3B](#f3){ref-type="fig"}), respectively. For bladder cancer, the multivariable HRs (95% CI) for CSS and OS were 2.52 (fixed-effects model; \[HR\] = 2.52, 95% CI = 1.60--3.96; p \< 0.01) ([Fig. 4A](#f4){ref-type="fig"}) and 2.95 (fixed-effects model; \[HR\] = 2.95, 95% CI = 1.81--4.80; p = 0.03) ([Fig. 4B](#f4){ref-type="fig"}). Five studies reported the prognostic role of CRP in upper urinary tract urothelial carcinoma and the multivariable HR for CSS was 2.96 (fixed-effects model; \[HR\] = 2.96, 95% CI = 2.12--4.14; p \< 0.01) ([Fig. 4C](#f4){ref-type="fig"}).

In order to explore whether CRP predicts the outcome of specific patients, we extracted the data on treatment and tumor stage. Among the 44 studies, only five studies including 763 localized RCC treated with nephrectomy evaluated the association between pretreatment CRP and CSS[@b22][@b24][@b30][@b38][@b58]. The multivariable HR (95% CI) for CSS was 3.66 (fixed-effect model; \[HR\] = 3.66, 95% CI = 2.20--6.09; p \< 0.01) ([Supplementary Figure S1A](#S1){ref-type="supplementary-material"} online). Another five studies included 585 cases and summarized that elevated pretreatment CRP was a poor predictor for OS in patients with metastatic RCC treated with molecular-targeted therapy[@b37][@b39][@b41][@b42][@b46] (random-effects model; \[HR\] = 1.86, 95% CI = 1.30--2.66; p \< 0.01) ([Supplementary Figure S1B](#S1){ref-type="supplementary-material"} online). In addition, CRP also predicted a poor survival in metastatic prostate cancer no matter treated with chemotherapy[@b15][@b19] (OS: fixed-effect model; \[HR\] = 2.18, 95% CI = 1.55--3.07; p \< 0.01) ([Supplementary Figure S1C](#S1){ref-type="supplementary-material"} online)or endocrine therapy[@b14][@b16] (CSS: fixed-effect model; \[HR\] = 1.92, 95% CI = 1.22--3.03; p \< 0.01) ([Supplementary Figure S1D](#S1){ref-type="supplementary-material"} online). We identified two studies that reported the effect of CRP on CSS in patients with localized upper urinary tract urothelial carcinoma (UUT-UC) treated with nephroureterectomy and their combined HR was 1.46 (fixed-effect model; \[HR\] = 1.45, 95% CI = 1.12--1.88; p \< 0.01) ([Supplementary Figure S1E](#S1){ref-type="supplementary-material"} online)[@b48][@b53].

Subgroup analysis
-----------------

As [Table 2](#t2){ref-type="table"} showed, the meta-analysis of all studies suggested a significant association between baseline serum CRP and CSS (random-effects model; \[HR\] = 1.97, 95% \[CI\] = 1.59--2.45; p \< 0.01). For overall survival, the multivariable HR (95% CI) of all studies was 1.99 \[random-effects model; \[HR\] = 1.99, 95% \[CI\] = 1.66--2.38; p \< 0.01).

Subgroup analyses by race showed that high CRP predicted a worse CSS (Caucasian: random-effects model; \[HR\] = 1.92, 95% CI = 1.34--2.75; p \< 0.01; Asian: random -effects model; \[HR\] = 1.87, 95% CI = 1.55--2.26; p \< 0.01). Similar role was shown for OS (Caucasian: random-effects model; \[HR\] = 1.74, 95% CI = 1.20--2.51; p \< 0.01; Asian: fixed-effect model; \[HR\] = 2.10, 95% CI = 1.83--2.41; p \< 0.01).

Studies were divided into two groups according to cutoff value. High CRP was shown to be a worse prognostic marker for CSS (cutoff ≤ 0.5: random-effects model; \[HR\] = 1.65, 95% CI = 1.33--2.04; p \< 0.01; cutoff \> 0.5: fixed-effect model; \[HR\] = 2.80, 95% CI = 2.14--3.66; p \< 0.01) and OS (cutoff ≤ 0.5: random-effects model; \[HR\] = 1.88, 95% CI = 1.47--2.42; p \< 0.01; cutoff \> 0.5: fixed-effect model; \[HR\] = 2.06, 95% CI = 1.70--2.49; p \< 0.01).

Meta-regression analysis
------------------------

We performed a meta-regression analysis to see the association between different cut-off values and HR ([Supplementary Figure S2](#S1){ref-type="supplementary-material"} online). For CSS, the results indicated that the association is greater when the cut-off value was higher (coefficient 0.68; p = 0.01). But no similar trend was observed in OS (coefficient 0.07; p = 0.56), which confirmed the results of subgroup analyses. To investigate the source of heterogeneity among studies, we conducted univariate meta-regression analyses by using variables as year of publication, race, tumor type, cutoff value and sample size suggested that the major sources of significant heterogeneity in studies on CSS were year of publication (coefficient = 0.07, p = 0.05, adjusted R^2^ = 0.13), tumor type (coefficient = 0.34, p = 0.02, adjusted R^2^ = 0.27) and cutoff value (coefficient = 0.68, p = 0.01, adjusted R^2^ = 0.33). For OS, only race (coefficient = −0.31, p = 0.06, adjusted R^2^ = 0.65) contributed to the heterogeneity. Then, a multiple meta-regression was carried out by using the five variables and we found these variables together could only explain heterogeneity in part (CSS: adjusted R^2^ = 42.4%; OS: adjusted R^2^ = 4.74%).

Publication bias
----------------

Publication bias was evaluated using Begg's funnel plot and the Egger's linear regression test. However, significant publication bias was found for OS (p = 0.36 for Begg's test and P \< 0.01 for Egger's test) and CSS (p = 0.09 for Begg's test and p \< 0.01 for Egger's test). Then, we conducted funnel plots adjusted with trim and fill method. As shown in [Fig. 5](#f5){ref-type="fig"}, ten theoretical studies were added in analysis of CSS and four in OS. The recalculated results did not change significantly for CSS (random-effects model; \[HR\] = 1.41, 95% CI = 1.26--1.58; p \< 0.01) ([Fig. 5A](#f5){ref-type="fig"}) and OS (random-effects model; \[HR\] = 1.49, 95% CI = 1.34--1.66; p \< 0.01) ([Fig. 5B](#f5){ref-type="fig"}), indicating the stability of the results.

Discussion
==========

To our knowledge, this is the most comprehensive meta-analysis studying the prognostic impact of CRP on urological cancers. Meanwhile, it is the first meta-analysis to evaluate the prognostic role of CRP in urothelial carcinoma/bladder cancer. Our results showed that elevated CRP was an independent prognostic marker in urological cancers, regardless of the tumor type, ethnicity background and cutoff value in the studies. Different pathological stages and treatment modalities could be correlated with the prognosis of cancers. However, few studies included in our meta-analysis analyzed these variables. In our meta-analysis, we evaluated the association between CRP and survival outcome of patients with different tumor stages or treated with different therapies. As we expected, the prognostic role of CRP was also confirmed in localized RCC treated with surgery, metastatic RCC treated with targeted therapy. Interestingly, the cutoff value of CRP should be carefully selected based on our results of meta-regression analysis. For CSS, the higher the cutoff value of CRP was, the higher HR was. However, there was no similar association between cutoff and overall survival in urological cancers.

The acute-phase reactant C-reactive protein is a member of the pentaxin protein family, mainly synthesized by hepatocytes, secreted into the circulation and mostly influenced by pro-inflammatory cytokines, particularly interleukin 6[@b59]. Apart from the liver, other tissues were able to synthesize the CRP. CRP is one of the major acute-phase proteins and is considered as a definitive marker of systemic inflammation. In clinical practice, it is commonly used to evaluate the severity of the systemic inflammation or outcomes of a variety of inflammation-related disorders[@b9]. In normal population, 70%--90% of samples have a CRP concentration of less than 0.3 mg/dl[@b60], while serum CRP level of cancer patients is significantly higher[@b61]. A possible explanation is that inflammatory cytokines secreted by tumor cells could strongly stimulate the CRP production in liver[@b62][@b63]. Additionally, some tumor cells could also secret CRP and that may contribute to the serum CRP level[@b64]. Therefore, serum CRP level of cancer patients could be an indirect indicator of cancer related inflammation.

Previous studies reported that elevated CRP was associated with poor prognosis in several kinds of malignancies[@b6][@b8]. Since the links between cancer and inflammation were reported and accepted, clinical value of CRP in various malignancies was noticed by more and more researchers. However, the mechanism is not yet fully understood. As mentioned above, elevated CRP in serum represents a systemic inflammatory response, which may indicate much inflammatory mediators from cancer tissue. Meanwhile, inflammatory microenvironment in tumor could activate some specific signaling pathways critical for proliferation, angiogenesis and metastasis of cancer[@b65]. Therefore, a systematic inflammatory response defined by elevated serum CRP could be associated with prognosis of urological cancers.

Here, we wish to emphasize several limitations of our study. First, even though the amount of included studies is large, the heterogeneity is relatively high and could not be eliminated completely. The five variables included in our meta-regression analysis partly explained heterogeneity. Other factors, such as age and histological grade, is likely to affect the prognosis. Second, some studies of urothelial carcinoma contained both bladder cancer and urothelial carcinoma of upper urinary tract so that we have to combine the bladder cancer and urothelial carcinoma into one group. Third, owing to lack of data, the association between CRP and other clinical parameters such as pathological stage and prostate-specific antigen (PSA) was not explored. Above all, additional well-designed studies are necessary to present more reliable results in urological cancers.

Conclusions
===========

In conclusion, current evidence from the meta-analysis of published studies identified elevated baseline serum CRP as a strong prognostic biomarker in urological cancers. However, limitations listed above should be noted and more large-scale and standard investigations should be carried out.

Methods
=======

Inclusion/exclusion criteria
----------------------------

Clinical studies were considered eligible if they investigated the association between pretreatment CRP in serum and survival outcome (OS, DSS or CSS) in patients who were diagnosed as urological cancer pathologically. No language or publication status restrictions were imposed. Studies were excluded based on any of the following criteria: (i) studies were review articles, laboratory articles or letters; (ii) HR was calculated with univariate rather than multivariable logistic regression analyses; (iii) papers lacked key information for calculation; (iv) a definite cutoff value of CRP wasn't given; (v) if two studies were published by the same group with overlapping patient populations, the most recent one was selected.

Literature search
-----------------

Studies were identified by searching electronic databases. A systematic literature search was carried out using PubMed and Embase databases. The literature search was undertaken in May 2014, and updated in October 2014. No language restriction was applied. We used the following search terms to search related studies: CRP; C-reactive protein; C reactive protein; renal cell carcinoma; bladder cancer; prostate cancer; urothelial cancer; transitional cell carcinoma. Search strategies are as following: Pubmed: C-reactive protein \[mesh\] AND (urinary bladder neoplasms \[mesh\] OR prostatic neoplasms \[mesh\] OR kidney neoplasms \[mesh\] OR carcinoma, transitional Cell \[mesh\]); EMBASE: C-reactive protein AND (bladder cancer OR prostate cancer OR renal cell carcinoma OR urothelial cancer OR urothelial carcinoma OR transitional cell carcinoma).

Study selection and quality assessment
--------------------------------------

After primary search, duplications are removed by screening the titles. Then, the titles and abstracts are reviewed for further evaluation. Finally, we will read the full-text for eligibility. If eligible, the study is included for the meta-analysis. Eligibility assessment was performed independently by two authors (L.Z. and X.C.). Disagreements were resolved by consensus. According to the review checklist of the Dutch Cochrane Centre proposed by Meta-analysis of Observational Studies in Epidemiology (MOOSE) group, we assessed the quality of all studies with the same method in Wu's work[@b12][@b66]. The quality criteria include (1) clear definition of study population, (2) clear definition of study design, (3) enough sample size more than 30, (4) clear definition of outcome assessment, OS or CSS, (5) clear definition of cut-off of CRP level and (6) sufficient period of follow-up.

Data extraction
---------------

Primary information, including hazard ratio (HR) and 95% confidence interval (CI) and p value, was extracted directly from articles by two investigators independently. Additional data were extracted from the studies, including the first author, year of publication, sample size, race, cutoff value and other clinical characteristics.

Statistical analysis
--------------------

The primary outcome measure was the hazard ratios of CRP predicting CSS, DSS or OS, which were obtained from each study. We combined CSS and DSS in an analysis due to similar definitions. Meta-analysis was performed to calculate the estimated hazard ratio and its variance. Results were shown in forest plot graphs. HR greater than 1 and 95% CI for the aggregated HR not crossing 1 indicates a prognostic role of elevated CRP. P \< 0.05 was considered statistically significant and all P values were two-sided. Heterogeneity was defined as p \< 0.10 or I^2 ^\> 50%. Random effects analysis of the Mantel Haenszel Model was utilized when statistical heterogeneity was suggested (p \< 0.10 or I^2 ^\> 50%). If not, a fixed effect model was used. If statistical heterogeneity was found (p \< 0.10 or I2 \> 50%), subgroup analysis and meta-regression were conducted to explore the potential source of heterogeneity among studies. In our study, subgroup analyses and meta-regression were conducted for tumor, race and cutoff value. Egger's test and Begg's test were performed to test for publication bias. Statistical analyses were done with Stata version 12.0 (STATA Corporation, College Station, TX, USA).
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###### Characteristics of all identified studies.

  Author        Year   Country   Tumor      N     Male   Metastatic   Outcome   Cut-off (mg/dl)
  ------------ ------ --------- -------- ------- ------ ------------ --------- -----------------
  Nakagawa      2014    Japan      BC      267    212       267         CSS           0.5
  Kramer        2014   Germany     BC      194    151        25         CSS           0.5
  Tanaka        2014    Japan    UUT-UC    564    409       122         CSS           0.5
  Sakano        2013    Japan    UUT-UC    536    370        0          DSS          0.13
  Kruck         2013   Germany    RCC      327    219        NA         CSS          0.25
  Kamba         2013    Japan     RCC      144    112       144         OS            0.3
  Shinohara     2013    Japan     RCC      473    329       473         OS            0.3
  Nakagawa      2013    Japan      BC      114     92        95         OS            0.5
  Beuselinck    2013   Belgium    RCC      200    142       200         OS            0.5
  Kwon          2013    Korea     RCC      106     78       106         OS            0.5
  Stein         2013   Germany   UUT-UC    115     83        26         CSS           0.5
  Kumano        2013    Japan     RCC      83      61        83         OS            0.8
  Yasuda        2013    Japan     RCC      52      42        52         OS            0.8
  Naito         2013    Japan     RCC      556    411       556         OS             1
  Herrel        2013   America    RCC      284    176        0          CSS            2
  Sakai         2013    Japan     RCC      164    130       164         OS             4
  Eggers        2013   Germany     BC      34      28        34         OS            0.8
  Steffens      2012   Germany    RCC     1,161   761       226         CSS           0.4
  Kinoshita     2012    Japan     RCC      559     NR       559         CSS            1
  Ito           2012    Japan     RCC      181    133       181         OS            1.8
  Komura        2011    Japan     RCC      170    114        0        CSS,OS          0.3
  Kume          2011    Japan     RCC      94      NR        94         OS            0.3
  Ito           2011    Japan      PC      80      80        80         OS            0.5
  Hotta         2011    Japan     RCC      105     76        18         OS            0.5
  Morizane      2011    Japan    UUT-UC    30      23        30         CSS            1
  Tomioka       2010    Japan      PC      287    287       265         OS            0.3
  Naya          2010    Japan     RCC      117     NR        0          CSS            1
  McArdle       2010     UK        PC      98      98        0        CSS,OS           1
  Iimura        2009    Japan     RCC      249    170        27         CSS           0.5
  Miyake        2009    Japan     RCC      52      35        52         CSS           0.5
  Saito         2009    Japan     RCC      108     80       108         OS            0.5
  Nakashima     2008    Japan      PC      126    126       126         DSS          0.15
  Kawata        2008    Japan     RCC      252    196        NA         CSS           0.3
  Yoshida       2008    Japan      BC      88      63        NA         CSS           0.5
  Beer          2008   Canada      PC      160    160       160         OS            0.8
  Ramsey        2008     UK       RCC      83      55        NA         CSS            1
  Komai         2007    Japan     RCC      101     63        0          DSS           0.5
  Saito         2007    Japan    UUT-UC    130     88        NA         DSS           0.5
  Vogl          2006    Japan     RCC      99      74        99         OS            0.8
  Hilmy         2006     UK        BC      103     70        0          CSS            1
  McArdle       2006     UK        PC      62      62        62         CSS            1
  Ito           2006    Japan     RCC      178     38        0          CSS            1
  Miyata        2001    Japan     RCC      92      71        19         CSS           0.5
  Ljungberg     1997   Sweden     RCC      196    119        66         OS             1

N, number of patients. Metastatic, number of patients with metastatic cancer. Cut-off: cut-off value of c-reactive protein (CRP) applied in each study. BC, bladder cancer. RCC, renal cell carcinoma. UUT-UC, upper urinary tract - urothelial carcinoma. DSS, disease specific survival. CSS, cancer specific survival. OS, overall survival. NA, not available.

###### Main results of subgroup analyses.

  Outcome      Variable   Number of studies        Model          HR(95%,CI)       I^2^    P~heterogeneity~
  ----------- ---------- ------------------- ----------------- ----------------- -------- ------------------
  CSS            All             25               Random        1.97(1.59,2.45)   81.5%         \<0.01
  Race                                                                                    
  Caucasian       9            Random         1.92(1.34,2.75)        82.7%        \<0.01  
  Asian           16           Random         1.87(1.55,2.26)        33.7%        \<0.01  
  Cut-off                                                                                 
  ≤0.5            16           Random         1.65(1.33,2.04)        78.2%        \<0.01  
  \>0.5           9             Fixed         2.80(2.14,3.66)        0.0%          0.65   
  OS             All             21               Random        1.99(1.66,2.38)   62.6%         \<0.01
  Race                                                                                    
  Caucasian       5            Random         1.74(1.20,2.51)        67.5%         0.02   
  Asian           16            Fixed         2.10(1.83,2.41)        0.0%          0.57   
  Cut-off                                                                                 
  ≤0.5            11           Random         1.88(1.47,2.42)        69.9%        \<0.01  
  \>0.5           10            Fixed         2.06(1.70,2.49)        5.7%          0.39   

Random: random-effects model. Fixed: fixed-effects model. P~heterogeneity~, P value for Cochran's Q test of heterogeneity.
